Pharmaceuticals 14 February 2026 - 9 March 2026

Olema Pharmaceuticals Shares Sink More Than 40% After Roche Trial Miss
···

Olema Pharmaceuticals Shares Sink More Than 40% After Roche Trial Miss

Olema Pharmaceuticals shares fell over 40% Monday after Roche’s breast cancer drug giredestrant failed to meet its main goal in a late-stage trial. Investors viewed the setback as a negative signal for Olema’s lead drug, palazestrant, which is in Phase 3 studies. Roche said the trial showed no significant improvement in progression-free survival. Olema ended September with $329 million in cash and expects top-line data in late 2026.
March 9, 2026
Xenon’s epilepsy drug posts strong Phase 3 data; XENE shares jump ahead of U.S. filing
···

Xenon’s epilepsy drug posts strong Phase 3 data; XENE shares jump ahead of U.S. filing

Xenon Pharmaceuticals said its Phase 3 trial showed azetukalner cut monthly focal onset seizures by 53.2% at the 25 mg dose versus 10.4% for placebo. Shares rose over 40% in premarket trading. The company plans to file for U.S. FDA approval in the third quarter of 2026. Dizziness was the most common side effect, with higher discontinuations in the 25 mg group.
March 9, 2026
Eli Lilly’s $449 Zepbound play: new “Employer Connect” targets workplace coverage gap
···

Eli Lilly’s $449 Zepbound play: new “Employer Connect” targets workplace coverage gap

Eli Lilly launched “Employer Connect” to let U.S. employers offer its obesity drug Zepbound at network pharmacies for $449 per dose. Partners include GoodRx, Teladoc Health, and Mark Cuban Cost Plus Drug Company. Lilly shares fell about 2% after the announcement. The company said final out-of-pocket costs will depend on each employer’s cost-sharing model.
March 6, 2026
OCUL stock dips in premarket after 23% pop as Ocular Therapeutix Axpaxli data sparks fresh targets
···

OCUL stock dips in premarket after 23% pop as Ocular Therapeutix Axpaxli data sparks fresh targets

Ocular Therapeutix shares fell 2.6% to $10.70 in premarket trading Tuesday after a 22.8% surge Monday, following detailed SOL-1 study results for Axpaxli in wet AMD. The company reported 74.1% of patients maintained vision at week 36 versus 55.8% on aflibercept. Clear Street raised its price target to $28, while Needham lowered its target to $18. Ocular will present at two healthcare conferences in March.
March 3, 2026
Eli Lilly stock rises as new orforglipron data puts side effects in the spotlight
···

Eli Lilly stock rises as new orforglipron data puts side effects in the spotlight

Eli Lilly shares rose 0.8% Friday after full trial results for its oral diabetes drug orforglipron showed higher discontinuation rates—8.7% to 9.7%—than Novo Nordisk’s oral semaglutide, which saw 4.5% to 4.9%. The study found orforglipron led to greater blood sugar and weight loss, but more side effects. Investors are watching for U.S. regulatory decisions on obesity use, expected in the second quarter.
February 27, 2026
Eli Lilly stock slips as new orforglipron data raises side-effect questions vs Novo pill
···

Eli Lilly stock slips as new orforglipron data raises side-effect questions vs Novo pill

Eli Lilly shares fell about 1% Thursday after new trial data showed its experimental weight-loss pill, orforglipron, caused more stomach-related side effects and patient dropouts than Novo Nordisk’s rival drug. The ACHIEVE-3 trial found Lilly’s pill led to greater blood sugar and weight reduction, but 10% discontinued due to side effects, double the rate seen with Novo’s oral semaglutide.
February 26, 2026
Eli Lilly stock price today: LLY slips as Zepbound pen rollout meets Novo’s trial, price-cut shocks
···

Eli Lilly stock price today: LLY slips as Zepbound pen rollout meets Novo’s trial, price-cut shocks

Eli Lilly shares fell 0.8% to $1,033.36 by midday Wednesday after two days of volatility in obesity-drug stocks. The drop followed Novo Nordisk’s decision to cut U.S. list prices for Wegovy and Ozempic by up to 50% starting in 2027. Traders cited shifting focus from supply concerns to pricing pressure. Lilly recently launched a new four-dose KwikPen for its Zepbound weight-loss drug at $299 per month.
February 25, 2026
Eli Lilly stock price dips after-hours as Zepbound pen news meets Novo’s Wegovy price-cut plan
···

Eli Lilly stock price dips after-hours as Zepbound pen news meets Novo’s Wegovy price-cut plan

Eli Lilly shares fell 1.6% to $1,042.15 Tuesday, then edged up 0.1% after hours, following FDA clearance of a four-dose Zepbound KwikPen for weight loss. The new device will cost $299 per month for cash customers. Novo Nordisk announced it will cut U.S. list prices for Ozempic and Wegovy by up to 50% starting in 2027. Investors weighed pricing moves and clinical trial results as competition intensified.
February 25, 2026
Eli Lilly stock price slips as Novo Nordisk signals Ozempic, Wegovy list-price cuts
···

Eli Lilly stock price slips as Novo Nordisk signals Ozempic, Wegovy list-price cuts

Eli Lilly shares fell 1.3% to $1,045.05 after Novo Nordisk said it will cut U.S. list prices for Ozempic and Wegovy to $675 a month starting January 2027. The move shifts investor focus to drug pricing and margins, despite Lilly’s recent clinical win over Novo’s CagriSema. Barclays slashed its peak sales forecast for CagriSema to $2 billion from $12 billion after new trial data.
February 24, 2026
Vanda Pharmaceuticals stock jumps 41% on Bysanti FDA approval filing as analysts weigh uptake risk
···

Vanda Pharmaceuticals stock jumps 41% on Bysanti FDA approval filing as analysts weigh uptake risk

Vanda Pharmaceuticals shares jumped 41% to $8.15 after the FDA approved its new antipsychotic, Bysanti, for schizophrenia and bipolar I disorder. The company expects a U.S. launch in the third quarter. Analysts questioned demand given similarities to Vanda’s older drug Fanapt, which faces generic competition in 2027 or 2028. Trading volume surged to 47.6 million shares, far above average.
February 23, 2026
AbbVie stock (ABBV): FDA clears new Venclexta-Calquence CLL combo — what to watch Monday
···

AbbVie stock (ABBV): FDA clears new Venclexta-Calquence CLL combo — what to watch Monday

U.S. regulators approved a new first-line regimen for chronic lymphocytic leukemia combining AbbVie’s Venclexta and AstraZeneca’s Calquence, citing improved progression-free survival in the AMPLIFY study. AbbVie shares closed Friday up 0.21% at $224.81. Barclays initiated coverage with an overweight rating and a $275 price target. Investors await market reaction when trading resumes Monday.
February 22, 2026
Grail stock halves after UK cancer trial miss; FDA and Medicare stakes rise
···

Grail stock halves after UK cancer trial miss; FDA and Medicare stakes rise

Grail shares fell about 50% to $50.21 in after-hours trading after its Galleri cancer blood test missed the main goal in a major UK trial. The study failed to show a statistically significant drop in late-stage cancers. Grail said it will release fuller data later this spring and extend trial follow-up. Investors are watching for U.S. regulatory and Medicare decisions.
February 20, 2026
Recursion Pharmaceuticals stock slides premarket as Novo Holdings exits stake — what to watch for RXRX
···

Recursion Pharmaceuticals stock slides premarket as Novo Holdings exits stake — what to watch for RXRX

Recursion Pharmaceuticals shares fell about 12% to $3.05 in premarket trading after a regulatory filing showed Novo Holdings A/S no longer reported a stake as of December 31. Novo had previously held nearly 8 million shares. Recursion closed at $3.46 on Tuesday. Investors await the company’s next earnings report and pipeline update.
February 18, 2026
Healthcare stocks head into Presidents Day break on Moderna rebound, Wegovy copycat fight
···

Healthcare stocks head into Presidents Day break on Moderna rebound, Wegovy copycat fight

The S&P 500 Health Care index rose 1.01% to 1,835.92 on Friday, with Dexcom up 7.6% and Moderna up 5.3% after earnings. Moderna warned of regulatory uncertainty after the FDA refused to review its flu shot. Disc Medicine shares fell 21% after the FDA declined to approve its rare-disease drug. U.S. markets close Monday for Presidents Day; Medtronic reports Tuesday.
February 14, 2026
AbbVie stock price climbs again after Botox lawsuit; what ABBV traders watch next
···

AbbVie stock price climbs again after Botox lawsuit; what ABBV traders watch next

AbbVie shares rose 1.8% to $231.50 in after-hours trading Friday following updates on its drug pipeline and ongoing litigation over Botox’s inclusion in Medicare price negotiations. Botox made up just over 10% of AbbVie’s $61.16 billion revenue last year. Investors are watching for mid-stage trial results in hidradenitis suppurativa and inflammatory bowel disease later this year. The next court update in the Botox case is expected Monday.
February 14, 2026
1 2